ICICI Prudential, Siemens can give up to 14% return in short term

Nifty closed at a 3-week low at 11,671 on October 29 and the breakdown of the 50-day average at 11,540 would accelerate the second round of profit-booking, pushing the index lower to 11,200.

Here are two buy and one sell calls for the next 3-4 weeks:

The stock has completed its corrective action from the recent high of Rs 487, completing its 25.2 percent retracement of the previous up-move from Rs 226 to Rs 487.

Weekly RSI has also reversed upwards from the lower range and 13-week corrective action confirms the reversal from the current levels.

Multiple support levels in the range of Rs 378-385 would protect the stock and they offer a good risk-reward ratio from the current levels.

The stock has closed at an 8-week high and its key technical indicators on the short-term timeframe have reversed giving a buy signal.

On the lower side, its prior low connecting support line and its 200-week SMA worked as a key reversal point.

We believe the stock will utilise prior consolidation and will resume its up-move and it could move towards Rs 1,400.

The stock has made a lower top and closed in an inside range of the previous week candle, suggesting a retracement on the downside.

It has multiple resistance near Rs 1,060-1,070, being 61.8 percent retracement from the recent bottoms.

The key technical indicators on the near-term timeframe chart are negatively poised. Any jump above Rs 1,060-mark will negate its down-move in the stock.

Disclaimer: Investment in securities markets are subject to Market Risk. Consult your financial advisor before any investments.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Indigo Paints trades at over 55% premium in grey market after IPO price announcement

The grey market premium has increased significantly from Rs 400-500 on January 11 to Rs 840-850 on January 15. Indigo Paints, one of the fastest-growing paint companies in India, was trading at more than 50 percent premium over its higher issue price band of Rs 1,490 per share in the grey market after the announcement of IPO details. The premium in the grey market as of January 15 was at around Rs 840-850 per share, which means the grey market trading price stood at Rs 2,340-2,330 against the issue price of Rs 1,490, as per the data available on IPO Watch. The premium increased significantly from Rs 400-500 on January 11 to Rs 840-850 today. The grey market is an unofficial trading platform where shares get traded well before the allotment in an initial public offering and till the shares get listed on bourses. It generally estimates the expected listing price of a stock. "Currently Asian paints and Berger paints are trading at a PE of 111 and 148, respectively, while Indigo Paint...

SD Solutions

Search This Blog